304 related articles for article (PubMed ID: 20368206)
21. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
22. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
Lipscombe LL; Gomes T; Lévesque LE; Hux JE; Juurlink DN; Alter DA
JAMA; 2007 Dec; 298(22):2634-43. PubMed ID: 18073359
[TBL] [Abstract][Full Text] [Related]
23. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
Patel RR
Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
[TBL] [Abstract][Full Text] [Related]
24. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Breunig IM; Shaya FT; McPherson ML; Snitker S
J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
[TBL] [Abstract][Full Text] [Related]
25. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
Buckingham RE; Hanna A
Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
[TBL] [Abstract][Full Text] [Related]
26. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
Odom J; Williamson B; Carter L
Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
[No Abstract] [Full Text] [Related]
27. The Yin and the Yang of CV risks in patients with diabetes.
Dangi-Garimella S
Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925
[No Abstract] [Full Text] [Related]
28. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Pinelli NR; Cha R; Brown MB; Jaber LA
Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
[TBL] [Abstract][Full Text] [Related]
29. Thiazolidinediones: the Forgotten Diabetes Medications.
Lebovitz HE
Curr Diab Rep; 2019 Nov; 19(12):151. PubMed ID: 31776781
[TBL] [Abstract][Full Text] [Related]
30. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
Singh S; Loke YK; Furberg CD
JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
[TBL] [Abstract][Full Text] [Related]
31. The new rosiglitazone story: its place today in type 2 diabetes management.
Ambery P; Pandya B
Prim Care Diabetes; 2009 Feb; 3(1):57-9. PubMed ID: 19269912
[TBL] [Abstract][Full Text] [Related]
32. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?
Lindberg M; Astrup A
Obes Rev; 2007 Sep; 8(5):381-4. PubMed ID: 17716295
[TBL] [Abstract][Full Text] [Related]
33. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli A; Formoso G
Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285
[TBL] [Abstract][Full Text] [Related]
34. Considerations for management of fluid dynamic issues associated with thiazolidinediones.
Hollenberg NK
Am J Med; 2003 Dec; 115 Suppl 8A():111S-115S. PubMed ID: 14678876
[TBL] [Abstract][Full Text] [Related]
35. The current role of thiazolidinediones in diabetes management.
Rizos CV; Kei A; Elisaf MS
Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418
[TBL] [Abstract][Full Text] [Related]
36. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
Berthet S; Olivier P; Montastruc JL; Lapeyre-Mestre M
BMC Clin Pharmacol; 2011 May; 11():5. PubMed ID: 21609444
[TBL] [Abstract][Full Text] [Related]
37. Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.
Roussel R; Hadjadj S; Pasquet B; Wilson PW; Smith SC; Goto S; Tubach F; Marre M; Porath A; Krempf M; Bhatt DL; Steg PG
Int J Cardiol; 2013 Aug; 167(4):1380-4. PubMed ID: 22560911
[TBL] [Abstract][Full Text] [Related]
38. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
[No Abstract] [Full Text] [Related]
39. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
Fonarow GC
Am Heart J; 2004 Oct; 148(4):551-8. PubMed ID: 15459582
[TBL] [Abstract][Full Text] [Related]
40. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
De Flines J; Scheen AJ
Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
